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MaOBJECTIVES This study aimed to compare whether reduced heart rate (HR) or higher beta-blocker (BB) dose affected
outcomes to a greater extent in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise
Training) trial population.
BACKGROUND Recent data have shown that HR is an important modiﬁable factor in reducing mortality in heart failure
(HF) patients. It has also been shown that titration of doses of BBs improves outcomes of morbidity and mortality in
chronic HF patients with reduced ejection fraction. We aimed to compare whether reduced HR or higher BB dose affected
outcomes to a greater extent in the HF-ACTION trial population.
METHODS HF-ACTION was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients with systolic
dysfunction (New York Heart Association functional class II to IV, left ventricular ejection fraction <0.35) randomized to
exercise training versus usual care, with median follow-up of 2.5 years. BB dose at baseline was standardized by use of
carvedilol equivalents. BB dose and HR were analyzed by discrete groups (higher/lower dose; higher/lower HR).
The relationship of BB dose, HR, and the primary endpoint of all-cause mortality or all-cause hospitalization and other
cardiovascular secondary endpoints were determined before and after adjustment for variables found to be signiﬁcantly
associated with outcome in the HF-ACTION cohort.
RESULTS Therewas a signiﬁcant inverse relationship between either BB dose (higher was better) or HR (lower was better)
and all-cause death or hospitalization in unadjusted analysis; however, only BB dose was signiﬁcant for improved mortality
outcomes. After adjustment for other predictors of outcome, only BB dose remained signiﬁcant for improving all-cause
death or hospitalization. BB dose, but not HR, was associated with improved outcomes of other cardiovascular endpoints in
unadjusted analysis but did not remain signiﬁcant when adjusted for other predictors of outcome in this cohort.
CONCLUSIONS There were more associated improvements in outcomes with higher BB dose than with reduced HR in
this well-treated HF cohort with systolic dysfunction, which suggests that titration of BB doses may confer a greater
beneﬁt than reduction of HR in such patients. (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise
Training [HF-ACTION]; NCT00047437) (J Am Coll Cardiol HF 2016;4:109–15) © 2016 by the American College of
Cardiology Foundation.m the aDuke University and Duke Clinical Research Institute, Durham, North Carolina; bMonteﬁore Einstein Center for Heart
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
BB = beta-blocker
HF = heart failure
HR = heart rate
LVEF = left ventricular ejection
fraction
NYHA = New York Heart
Association
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110B eta-blockers (BBs) are an importantpharmacological therapy that reducesmorbidity/mortality in patients with
heart failure (HF) with reduced left ventricu-
lar ejection fraction (LVEF) (1).
In the only study prospectively designed
to test dose-response relationships with the
BB carvedilol in patients with systolic HF,
Bristow et al. (2) reported dose-related im-
provements in LVEF and survival. We have
previously shown that in the HF-ACTION(Heart Failure: A Controlled Trial Investigating Out-
comes of Exercise Training) cohort, higher BB dose
was associated with a signiﬁcant reduction in
all-cause hospitalization and all-cause death, even
after adjustment for important prognostic covariates,
which suggests that BB therapy should be titrated to
moderate to high doses (3).
Recent data have shown that heart rate (HR) is an
important modiﬁable factor in reducing mortality in
HF patients (4,5). Although HR lowering is an
important effect of BBs, the prognostic beneﬁts are
not entirely related to reducing HR (1). In an analysis
from the COMET (Carvedilol or Metoprolol European
Trial), the investigators demonstrated that both the
HR achieved during BB therapy and BB dose were
independently associated with outcomes (6); how-
ever, studies have shown a survival beneﬁt based on
HR lowering alone rather than BB dose achieved (7,8).
Furthermore, in a large randomized trial of the drug
ivabradine, a selective HR-lowering agent, clinical
outcomes were signiﬁcantly improved compared with
placebo (9).
The HF-ACTION trial was the largest trial to date to
test the effects of exercise training versus usual care
in HF patients with moderate to severe left ventric-
ular systolic dysfunction (10). We aimed to examine
the relationship between baseline BB dose, baseline
HR, and outcomes in the HF-ACTION study popula-
tion, hypothesizing that titrating patients to higher
BB doses versus lowering HR may confer a greater
beneﬁt on cardiovascular outcomes.
METHODS
The HF-ACTION trial design and outcomes have been
described previously (10,11). Brieﬂy, the study was a
multicenter, randomized controlled trial testing the
long-term safety and efﬁcacy of aerobic exercise
training plus evidence-based medical therapy versus
evidence-based medical therapy alone in medically
stable outpatients with left ventricular systolic
dysfunction (LVEF <35%) and New York Heart
Association (NYHA) functional class II to IV HF. Adultsubjects receiving angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers and beta-
adrenergic blockade for $6 weeks (unless there was
a documented rationale for variation) were eligible.
The primary endpoint was the composite of death or
all-cause hospitalization. Patients were randomly
assigned to usual care alone or usual care plus exer-
cise training, which consisted of a prescription of
supervised aerobic exercise training at 60% to 70% of
HR reserve 3 times per week, followed by home-based
training at the same intensity 5 times per week,
totaling 36 sessions. Randomization was stratiﬁed by
center and HF pathogenesis. Participants were fol-
lowed up for a median of 2.5 years.
DATA CONSIDERATIONS AND OUTCOME MEASURES.
Patient characteristics, health status, laboratory
values, and physiological parameters at rest and
during a cardiopulmonary exercise test were
collected on standardized forms at baseline and at
several points throughout the study (laboratory
values only at baseline). HR was measured at rest
after patients had been sitting for 5 min before
assessment. BB dose at baseline was standardized by
use of carvedilol equivalents and analyzed by
discrete dose groups (high dose $25 mg daily vs. low
dose <25 mg daily). Resting HR was also analyzed
by discrete groups (high $70 beats/min vs. low
<70 beats/min).
The composite primary endpoint of all-cause mor-
tality and all-cause hospitalization, as well as an
endpoint of mortality alone, were determined and
adjusted with variables found to be signiﬁcantly
associated with outcomes (12). Other pre-speciﬁed
secondary endpoints included cardiovascular mortal-
ity or cardiovascular hospitalization, cardiovascular
mortality alone, and cardiovascular mortality or HF
hospitalization. Although atrial ﬁbrillation (AF) was
not a predictor of outcomes in this cohort, we ran a
sensitivity analysis to exclude patients with AF aswell.
A subset of patients enrolled in the HF-ACTION
study agreed to participate in the biomarker sub-
study and underwent plasma collection at baseline,
3 months, and 12 months. Changes were assessed in
928 patients with data available on serial changes.
STATISTICAL METHODS. Baseline characteristics were
summarized by counts and percentages for categori-
cal variables and by medians with interquartile
ranges for continuous variables. For the primary
endpoint (all-cause death or hospitalization) and
secondary endpoint (all-cause death), adjustment
models were developed with a broad range of candi-
date variables, including demographics, past medical
history, laboratory values, exercise test values, and
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111quality-of-life indices (Kansas City Cardiomyopathy
Questionnaire). These models were used for adjust-
ment in this analysis. Cox proportional hazards
modeling was used to assess the relationship between
outcomes and BB dose or HR, before and after
adjustment for the variables found to be signiﬁcantly
associated with each endpoint. The proportional
hazard assumption was assessed with weighted
Schoenfeld residuals. A 2-tailed p value #0.05 was
considered statistically signiﬁcant for all analyses.
Statistical analysis was performed by the Duke Clin-
ical Research Institute using SAS software version
9.2 (Cary, North Carolina).
RESULTS
Of the 2,331 patients enrolled in the HF-ACTION study,
only 128 (5.5%) were not taking a BB. This analysis
included 2,320 patients; 5 patients with missing HR
information at baseline were excluded. Baseline
characteristics are shown in Table 1. The clinical
characteristics of patients across all groups were
similar, particularly with regard to systolic blood
pressure, LVEF, and functional capacity at baseline. Of
note, HR at peak exercise was 118 beats/min in the
high-dose group versus 122 beats/min in the low-dose
group and 123 beats/min in the high-HR group versus
114 beats/min in the low-HR group, which indicates
that there was a true beta-blockade effect with the
higher doses.TABLE 1 Baseline Characteristics by Beta-Blocker Dose and HR at Ra
Characteristics
Beta-Blocker Dose
High ($25 mg/d)
(n ¼ 1,655)
Low (<
(n ¼
Age, yrs 59 (50–67) 62 (5
Female 27.1 3
Black 34.4 2
BMI, kg/m2 31 (27–36) 28 (2
NYHA functional class II 65.4 5
Ischemic HF etiology 49.4 5
SBP, mm Hg 112 (100–126) 110 (1
LVEF, % 25 (20–30) 24 (1
History of diabetes 33.7 2
BUN, mg/dl 20 (15–27) 22 (1
Sinus rhythm at baseline 81.3 7
HR at rest, beats/min 71 (64–79) 70 (6
HR at peak exercise, beats/min 118 (103–133) 122 (1
CPX duration, min 9.8 (7.0–12.0) 9.2 (6
6MWT distance, m 374 (300–437) 366 (2
Peak VO2 14.5 (11.6–17.7) 14.1 (1
Values are median (interquartile range) or %.
6MWT ¼ 6-min walk test; BMI ¼ body mass index; BUN ¼ blood urea nitrogen; CPX ¼
ejection fraction; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure; VThe relationship between all-cause death/hospi-
talization and BB dose/HR groups is shown in
Figure 1, and the clinical outcomes are shown in
Table 2. There was a signiﬁcant inverse relationship
between either BB dose (higher was better) or HR
(lower was better) and all-cause death or hospitali-
zation in unadjusted analysis; however, after adjust-
ment for the variables found to be signiﬁcantly
associated with the primary endpoint, higher BB dose
remained signiﬁcantly associated with improved
outcomes regardless of high or low HR (hazard ratio:
0.77; p ¼ 0.03 [95% conﬁdence interval: 0.7 to 0.86]).
A low BB dose combined with a high HR conferred the
worst outcomes for this endpoint. The proportional
hazard assumption was not met for HR for any of the
5 endpoints presented in Table 2 (unadjusted and
adjusted) or for BB dose with all-cause death and
cardiovascular death. The violation of the propor-
tional hazard assumption was explored for each
endpoint. In all cases, no crossing of the estimated
hazard function was observed. Estimated hazard ra-
tios in these cases represent average hazard ratios
during the follow-up period and should be inter-
preted with caution. In a sensitivity analysis that
excluded patients with AF or history of AF (n ¼ 487),
no difference was found from the primary results
(Online Table 1).
Only BB dose was signiﬁcant for improved out-
comes on mortality in unadjusted analysis regard-
less of HR (Figure 2), but not after multivariablendomization
HR
25 mg/d)
670)
High ($70 beats/min)
(n ¼ 1,211)
Low (<70 beats/min)
(n ¼ 1,109 )
4–70) 57 (49–66) 61 (53–70)
1.6 29.1 27.8
8.4 35.2 30.0
5–33) 31 (27–36) 29 (26–34)
8.5 60.0 67.1
6.0 45.1 58.2
00–124) 110 (100–124) 112 (100–128)
9–30) 24 (19–30) 25 (21–31)
7.9 34.4 29.5
6–31) 20 (15–28) 21 (16–28)
8.8 78.8 82.6
2–76) 77 (72–84) 62 (60–66)
07–139) 123 (111–139) 114 (98–129)
.5–11.8) 9.4 (6.6–11.6) 10.0 (7.2–12.7)
89–429) 366 (290–429) 377 (311–439)
1.3–17.5) 14.2 (11.3–17.4) 14.7 (11.7–17.9)
cardiopulmonary exercise; HF ¼ heart failure; HR ¼ heart rate; LVEF ¼ left ventricular
O2 ¼ peak oxygen uptake.
FIGURE 1 All-Cause Death or Hospitalization by BB Dose (High/Low) and HR (High/Low) at Baseline
Estimated risk of death or hospitalization by discrete groups (high BB dose/high HR; high BB dose/low HR; low BB dose/high HR;
low BB dose/low HR). BB ¼ beta-blocker; HR ¼ heart rate.
TABLE 2 Association Between Beta-Blocker Dose* at Baseline, Resting Heart Rate at Baseline, and Endpoints
Unadjusted Adjusted*,†
Chi-Square p Value HR (95% CI) Chi-Square p Value HR (95% CI)
All-cause death or all-cause rehospitalization
Beta-blocker effect (high vs. low dose)‡ 21.8 <.0001 0.77 (0.7–0.86) 4.7 0.03 0.87 (0.77–0.99)
Heart rate effect (heart rate $70 vs. <70 beats/min) 6.4 0.01 1.14 (1.03–1.26)§ 2.9 0.09 1.11 (0.98–1.24)§
Beta-blocker by heart rate 3.5 0.06 1.8 0.19
All-cause death
Beta-blocker effect (high vs. low dose) 4.9 0.027 0.79 (0.64–0.97)§ 0.32 0.57 0.94 (0.75–1.17)§
Heart rate effect (heart rate $70 vs. <70 beats/min) 0.05 0.82 0.977 (0.800–1.194)§ 1.26 0.26 0.89 (0.72–1.09)§
Beta-blocker by heart rate 0.45 0.50 0.53 0.47
CV death
Beta-blocker effect (high vs. low dose) 2.74 0.098 0.80 (0.62–1.04)§ 0.24 0.62 0.93 (0.71–1.23)§
Heart rate effect (heart rate $70 vs. <70 beats/min) 0.37 0.54 0.93 (0.72–1.19)§ 2.45 0.12 0.81 (0.63–1.05)§
Beta-blocker by heart rate 0.02 0.88 0.06 0.80
CV death or CV rehospitalization
Beta-blocker effect (high vs. low dose) 10.43 0.001 0.82 (0.73–0.93) 1.22 0.27 0.93 (0.81–1.06)
Heart rate effect (heart rate $70 vs. <70 beats/min) 2.06 0.15 1.083 (0.971–1.207)§ 0.05 0.8227 1.02 (0.89–1.15)§
Beta-blocker by heart rate 4.17 0.04 3.01 0.0828
CV death or HF rehospitalization
Beta-blocker effect (high vs. low dose) 10.71 0.001 0.77 (0.66–0.90) 1.40 0.2360 0.896 (0.747–1.074)
Heart rate effect (heart rate $70 vs. <70 beats/min) 5.83 0.016 1.197 (1.03–1.38)§ 0.47 0.49 1.06 (0.9–1.26)§
Beta-blocker by heart rate 3.27 0.07 2.94 0.086
*With adjustment by Kansas City Cardiomyopathy Questionnaire symptom stability, left ventricular ejection fraction, region, sex, ventricular conduction, Weber class, blood
urea nitrogen, and mitral regurgitation. †With adjustment by sex, body mass index, loop diuretic agents, Canadian Cardiovascular Society angina class, creatinine, exercise
duration, ventricular conduction, and left ventricular ejection fraction. ‡High-dose beta-blocker deﬁned as $25 mg daily carvedilol equivalents; patients not taking
beta-blockers were included in the low-dose group. §Proportional hazard assumption not valid; hazard ratio represents an average hazard ratio during follow-up.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; HR ¼ hazard ratio.
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FIGURE 2 All-Cause Death by BB Dose (High/Low) and HR (High/Low) at Baseline
Estimated risk of death by discrete groups (high BB dose/high HR; high BB dose/low HR; low BB dose/high HR; low BB dose/low HR).
BB ¼ beta-blocker; HR ¼ heart rate.
TABLE 3 Change in NT-proBNP From Baseline
n Median (25th–75th) Minimum–Maximum
3 months
Low BB dose/low heart rate 135 4 (299 to 253) 4,010 to 7,112
Low BB dose/high heart rate 149 54 (449 to 231) 6,224 to 17,235
High BB dose/low heart rate 340 19 (231 to 197) 7,843 to 11,327
High BB dose/high heart rate 301 64 (365 to 130) 8,675 to 18,216
12 months
Low BB dose/low heart rate 85 14 (417 to 264) 2,507 to 4,311
Low BB dose/high heart rate 101 87 (464 to 180) 6,348 to 5,821
High BB dose/low heart rate 215 46 (255 to 175) 8,376 to 4,379
High BB dose/high heart rate 191 57 (343 to 139) 6,980 to 19,733
p Value for comparison of changes at 3 months ¼ 0.12; p value for comparison of changes at 12 months ¼ 0.45.
BB ¼ beta-blocker; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide.
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113adjustment. However, the lack of a signiﬁcant associ-
ation between BB dose and other events, in addition to
the primary outcome of the study, may have been
caused by the relative underpowering of the study
group caused by the relatively low number of events.
Although each of the other cardiovascular endpoints
showed a similar signiﬁcant inverse relationship with
BB dose in a univariate model, these became nonsig-
niﬁcant when adjusted for other clinical variables.
With regard to biomarker changes, there did not
appear to be any statistically signiﬁcant difference in
changes in N-terminal pro-brain natriuretic peptide
(NT-proBNP) between the groups, although there did
appear to be a greater absolute change in the higher-
dose groups (Table 3). It is likely the numbers were
too small to detect a statistical difference. Finally, we
have previously shown no increased risk of brady-
cardia with higher doses of BB in this cohort (3).
DISCUSSION
There are several important ﬁndings from this study.
First, patients taking low-dose BB who had high HRs
had the worse outcomes for the endpoint of all-
cause mortality and hospitalizations; however, after
adjustment for important clinical variables, only
higher BB dose remained signiﬁcantly associatedwith improved outcomes. There was a signiﬁcant
relationship between BB dose (higher was better)
and all-cause death; however, no signiﬁcant rela-
tionship between BB dose and death or secondary
outcomes was observed after adjustment for other
clinical variables.
This study found an association between higher
doses of beta-blockade and an improvement in
the primary composite endpoint of all-cause death/
hospitalization, regardless of baseline HR being high
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114or low. The possibility for this has been demonstrated
in other studies. For example, in a post-hoc subgroup
analysis of the MERIT-HF (Metoprolol CR/XL Ran-
domized Intervention Trial in Chronic Heart Failure),
no dose-response relationship with mortality was
observed for metoprolol CR/XL in the overall cohort,
but a wide variation in dose response existed be-
tween patients. HR reduction was similar across
3 dose groups, which indicates the degree of beta-
blockade may have been equivalent and thus limits
the ability to test a true association between dose and
mortality beneﬁt, because previous studies have
demonstrated that the degree of HR reduction
may be related to outcome (13,14). With recent
advances in therapies that target HR alone, this study
suggests that BB dose should be optimized before HR
is treated. Although guidelines recommend moderate
to high doses of BBs, many patients’ medications
are not titrated to those doses. Data from the
OPTIMIZE-HF (Organized Program to Initiate Life-
saving Treatment in Hospitalized Patients With Heart
Failure) registry showed that in patients hospitalized
for HF, the mean daily dose of BBs before ho-
spital admission was one-half the recommended
target dose, and most patients were not titrated to
target doses at 90 days post-discharge. At 60 and 90
days post-discharge, only 17.5% and 7.9% of patients
were receiving target doses of BBs, respectively (15).
In part, this reluctance to titrate doses may be based
on lack of deﬁnitive evidence that there are
improved outcomes with higher doses, as well as
health system barriers that prevent easy titration of
the medications to target doses, and a concern about
an increase in adverse events, particularly in those
who are older or frail or have signiﬁcant comorbid-
ities (16). A recent study of prescribing patterns in a
community HF clinic showed that of 1,000 appoint-
ments for HF patients with reduced ejection fraction,
70 clinic visits were eligible for intervention (17). Of
those, 58 patients were in sinus rhythm and had an
HR $70 beats/min, and BB dose was increased in only
13 patients. Twenty additional patients were
eligible for BB dose titration (15 were already at
target doses, 10 were intolerant to higher doses) but
did not have any change in dose. The
authors concluded that 12% of patients would be
eligible for ivabradine, an intervention to target HR
alone.
The evidence for a BB dose-response relationship
has been limited in cardiovascular medicine. The
MOCHA (Multicenter Oral Carvedilol Heart Failure
Assessment) study demonstrated a positive dose-
response relationship between BB dose and LVEFimprovement and an improvement in survival (2);
however, the cohort of 300 patients with only
30 deaths make the ﬁndings regarding survival difﬁ-
cult to interpret. A meta-analysis of BB dose and
clinical outcome in HF patients found no signiﬁcant
relationship between all-cause mortality and BB dose
(7); however, there were important limitations, as
with any meta-analysis. We have previously shown
that approximately one-half the patients in HF-
ACTION were not at target doses and that there was
no increased risk of bradycardia with higher doses,
which suggests there is considerable room for BB up-
titration in clinical practice (3). This is particularly
reassuring if adverse events are a concern that pre-
vents dose titration. There remains no deﬁnitive ev-
idence of a dose-response relationship between BB
therapy and outcomes in a randomized controlled
trial.
STUDY LIMITATIONS. Our ﬁndings should be inter-
preted in the context of several potentially important
limitations. First, this is a post-hoc analysis.
Although this study population is broad, patients
who were not ambulatory were excluded. On the
other hand, this study includes a relatively large
cohort of women and black patients. Additionally,
changes in BB dose and HR during follow-up and
incident AF were not captured in this analysis. An
important potential confounder is that sicker patients
may be less able to tolerate higher BB doses.
Although we adjusted for numerous known pre-
dictors of adverse outcome, the possibility of impor-
tant unidentiﬁed prognostic indicators must be
considered.
CONCLUSIONS
After adjustment for important clinic variables, a
higher BB dose in ambulatory HF patients with
reduced ejection fraction was associated with a sig-
niﬁcant reduction in all-cause hospitalization and
all-cause death, regardless of baseline HR being
high or low. This study suggests that the titration
of BB doses may confer a greater beneﬁt than a
reduction in HR in such patients and supports
the current clinical guideline recommendations that
BB therapy should be titrated to moderate to
high doses as used in randomized controlled clinical
trials.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This
study demonstrates an important question for patient
care, particularly because new agents are available that
target HR alone. Our data suggest that titration of BB
doses should be considered as ﬁrst-line therapy in clinical
decision making.
TRANSLATIONAL OUTLOOK: These data support the
need for a deﬁnitive randomized controlled trial exam-
ining a dose-response relationship between BB therapy
and outcomes.
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